Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A female between, and including, 9-13 years (before 14th birthday) and 16-26 years of age (before 27th birthday) at the time of the first vaccination.~* Healthy~* Not pregnant~* Four or less sexual partners over lifetime as reported by subject. (Sexual activity is defined as intercourse)~* Not planning to become pregnant or likely to become pregnant~* No reported history of genital warts~* No laboratory confirmed history of cervical intraepithelial neoplasia~* No previous vaccination against HPV~* No administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period~* No previous anaphylactic reaction to HPV vaccine or any vaccine related component including aluminum hydroxyphosphate sulfate and polysorbate 80~* No confirmed or suspected immunosuppressive or immunodeficient condition based on medical history~* No bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~* Cannot be already enrolled in any clinical trial in which investigational vaccine or drug are being administered~Exclusion Criteria~* Pregnant~* Female planning to become pregnant or likely to become pregnant (as determined by the investigator) during the study duration Part 1 (0-7 months)~* Reported history of genital warts~* Laboratory confirmed history of cervical intraepithelial neoplasia~* Greater than four lifetime sexual partners involving sexual intercourse~* Previous vaccination against HPV~* Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period~* A previous anaphylactic reaction to HPV vaccine or any vaccine related component including aluminum hydroxyphosphate sulfate and polysorbate 80~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history (e.g. HIV infection, genetic defect, immunosuppressive therapy). \*Chronic administration (defined as more than 14 days) of immune-modifying drugs within 6 months prior to the first vaccine dose or planned use during the study period is exclusionary (corticosteroid use - immune-modifying level is ≥0.5 mg/kg/day; inhaled or topical steroids are acceptable).~* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection (thrombocytopaenia, coagulation disorder, anti-coagulant therapy).~* Enrollment in any clinical trial in which investigational vaccine or drug are being administered

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- 16-26 year olds 3 doses HPV Vaccine (Type: ACTIVE_COMPARATOR): Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
- 3 dose 9-13 HPV Vaccine (Type: ACTIVE_COMPARATOR): Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
- 2 dose 9-13 yrs HPV Vaccine (Type: ACTIVE_COMPARATOR): Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete